Multiple Myeloma

Latest News

September 6th 2023

Multiple Myeloma: Data on Outcomes Based On Cytogenetics

By Peter Voorhees, MD, Kwabena Osei-Boateng, MD, Amy Soni, MD

Key opinion leaders in the field of multiple myeloma review data looking at patient outcomes in the GRIFFIN and MASTER trials based on cytogenetic abnormalities.

Latest Videos

Treating Patients Referred to Academic Centers for CAR T

Identifying Potential Candidates for CAR T-Cell Therapy

Beth Faiman, CNP, PhD, an expert on multiple myeloma

Patient Profile 1: Managing CRS Following CAR T-Cell Therapy

A panel of 4 experts on multiple myeloma

MM Treatment: CAR T-Cell Therapy Selection and Insurance Considerations

Future Perspectives on CAR T-Cell Therapy in Relapsed/Refractory MM

Patient Profile: A 66-Year-Old with IgG Kappa MM

Navigating CAR T-Cell Therapy in Multiple Myeloma: A Collaborative, Patient-Centered Approach

Unique Challenges in Managing Adverse Events Associated with CAR T-Cell Therapy

Whether CAR T-cell therapy or T-cell engagers should dominate the multiple myeloma landscape may be hard to determine, says David S. Siegel, MD.

Leveraging “Exciting” CAR T-Cell Therapy Advancements in Multiple Myeloma

Next steps for research in the multiple myeloma space may include the development of novel CAR T-cell strategies and bispecific antibodies.

Building On Outcomes With Isatuximab in Newly Diagnosed Myeloma

CME Content

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Iowa Oncology Society

Marla D. Lipsyc-Sharf, MD; Sheila Donnelly, MD

Video

Show Me the Data™: Post-TKI Sequencing in EGFR-Mutated NSCLC—Optimizing Current Strategies and Preparing for New Treatment Modalities

Christine M. Lovly, MD, PhD, FASCO; Xiuning Le, MD, PhD; Hossein Borghaei, DO, MS; Lyudmila Bazhenova, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Texas Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Parth Khade, MD

Video

22nd Annual International Symposium on Melanoma and Other Cutaneous Malignancies®

Omid Hamid, MD; Sapna Patel, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | North Carolina Oncology Association

Marla D. Lipsyc-Sharf, MD; Yan Ji, MD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | New Mexico Society of Clinical Oncology

Marla D. Lipsyc-Sharf, MD; Kimberly Ku, MD

Video

Addressing Unmet Needs in HER2+ Metastatic BTC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Ghassan Abou-Alfa, MD, MBA

Multimedia

Community Practice Connections™: Tailored Treatment Approaches for Older Patients With Advanced HR+/HER2– Breast Cancer

Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Komal Jhaveri, MD, FACP

Multimedia

Community Practice Connections™: Optimizing Treatment Outcomes and Preserving Fertility in Premenopausal HR+ Breast Cancer

Rebecca Shatsky, MD; Kelly McCann, MD, PhD; Michelle L. Taylor, ANP-BC

Video

From Bench to Bedside: Paradigm Shifts in HER2+ Metastatic BTC Treatment

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Shubham Pant, MD, MBBS

Video

Proactive Adverse Event Management for HER2+ BTC Treatments

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Rachna T. Shroff, MD, MS, FASCO

Multimedia

Community Practice Connections™: Empowering Interventional Radiologists in the Emerging Era of Oncolytic Immunotherapies for Melanoma

Yana G. Najjar, MD; Douglas B. Johnson, MD, MSCI; Rahul A. Sheth, MD, FSIR

Video

A Case-Guided Discussion on Managing Immune Thrombocytopenic Purpura (ITP)

Cindy Neunert, MD, MSCS; Hanny Al-Samkari, MD; Joseph Shatzel, MD, MCR

Video

Medical Crossfire®: Integrating Next-Generation Endocrine Targeting Therapies to Improve Outcomes for Patients With HR+/HER2- Breast Cancer

William J. Gradishar, MD, FASCO, FACP; Laura Huppert, MD; Yuan Yuan, MD, PhD

Video

PER Tumor Board®: Applying Recent Advances to Transform the Treatment Paradigm in SCLC—Expert Perspectives on New Approvals and Emerging Strategies

Jonathan W. Goldman, MD; Percy Lee, MD, FASTRO; Erminia Massarelli, MD, PhD, MS; Misty D. Shields, MD, PhD

Video

Medical Crossfire®: Harnessing the Power of Modern Therapies in Newly Diagnosed Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

GI Tumor Board—Applying Recent Advances in Biomarker Testing and Treatment in Metastatic Colorectal Cancer

John H. Strickler, MD; Stacey A. Cohen, MD; Aparna Parikh, MD; Kanwal P.S. Raghav, MBBS, MD

Video

Evolving Treatment Strategies in Pancreatic Cancer: Current Standards, Emerging Targets, and the Role of Molecular Testing

Eileen M. O’Reilly, MD; E. Gabriela Chiorean, MD, FASCO; Michael J. Pishvaian, MD, PhD; Brian Wolpin, MD, MPH

Video

Cases & Conversations™: Transforming AML Care—Precision Strategies, Evolving Therapies, and Clinical Insights

Gail J. Roboz, MD; Hagop Kantarjian, MD; Catherine Lai, MD, MPH; Amer Zeidan, MBBS, MHS

Video

Tumor Board: Expert Insights on Managing Classical 𝘌𝘎𝘍𝘙 Mutations, 𝘌𝘎𝘍𝘙 Exon 20 Insertions, and Atypical 𝘌𝘎𝘍𝘙 Mutations in Metastatic NSCLC

Balazs Halmos, MD, MS; Enriqueta Felip, MD, PhD; Julia Rotow, MD

Video

Medical Crossfire®: Improving Patient Outcomes in Myeloproliferative Neoplasms With Novel Therapeutic Approaches

Rami Komrokji, MD; Gabriela Hobbs, MD; John Mascarenhas, MD; Naveen Pemmaraju, MD

Multimedia

Evaluating the Latest Data and Ongoing Trials for Novel ADC Approaches in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD

Multimedia

Breaking Down the Rationale for Targeting TROP2 in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Audio

Breaking Down the Latest Clinical Data for First-line Maintenance and R/R SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Hossein Borghaei, DO, MS

Video

Cross-Disease Integration of Immunotherapy Innovations

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Video

Optimizing Treatment for Biliary Tract Cancers

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Multimedia

PER Resource Center: Integrating Novel Approaches in TNBC – New Avenues for TROP2-Targeting ADCs and Beyond – Nursing

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc; Filipa Lynce, MD; Rita Nanda, MD; Tiffany A. Traina, MD, FASCO

Video

Show Me the Data®: New and Emerging Roles for Oral SERD Therapy in the Treatment of ER+/HER2– Breast Cancer

Ana C. Garrido-Castro, MD; Pedram Razavi, MD, PhD

Multimedia

Ready for Radioligand Therapy? Patient Selection and Sequencing Simplified

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Working Together: Overcoming Barriers to Optimize Outcomes in Patients Treated With Radioligand Therapy Through Multidisciplinary Care

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Video

(CME Track) Live Tumor Board: Squamous Cell Carcinoma of the Head & Neck - Post-CRT Decisions in the Locally Advanced Setting

Quynh-Thu Le, MD, FACR, FASTRO; Vlad C. Sandulache, MD, PhD

Video

Community Oncology Connections™: Beyond Primary End Points – Digging Into Randomized and Real-World Data to Guide Challenging Treatment Decisions in HR+/HER2− Metastatic Breast Cancer | Rocky Mountain Oncology Society

Seth A. Wander, MD, PhD; Kara M. Schenk, MD

Virtual Event

Oncology Town Hall - Translating the Latest Updates Into the Care of Patients With AML in Community Practices

April 9, 2026

In-Person + Virtual Event

11th Annual School of Gastrointestinal Oncology® (SOGO®)

April 11, 2026

In-Person + Virtual Event

Tumor Board: Clinical Integration of Molecular Profiling in Glioma - Transforming the Use of Targeted Therapy

April 20, 2026

Video

Medical Crossfire®: Expert Perspectives on Targeting c-Met Overexpression and 𝘔𝘌𝘛 Genomic Alterations in NSCLC – Unveiling the Complexities of 𝘔𝘌𝘛 Dysregulation

Rebecca Heist, MD, MPH; Alex A. Adjei, MD, PhD, FACP; Sandip Patel, MD, FASCO; Jeremy Segal, MD, PhD

Video

Medical Crossfire®: Precision Medicine in Glioma Treatment — Integration of Molecular Profiling to Inform Targeted Therapies

Vinay K. Puduvalli, MD; Manmeet Ahluwalia, MD, MBA; Stephen J. Bagley, MD, MSCE; Angela Waanders, MD, MPH, MS

$Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma$

Video

Cases and Conversations™: Sorting Through the Expanding Treatment Options for Patients with Relapsed/Refractory Multiple Myeloma

C. Ola Landgren, MD, PhD; Mohamad Mohty, MD, PhD; Surbhi Sidana, MD

Video

Breast Cancer Tumor Board: Targeting TROP2 – Innovations in Triple-Negative Breast Cancer Treatment

Joyce O’Shaughnessy, MD; Matthew P. Goetz, MD; Hope S. Rugo, MD, FASCO

Multimedia

Establishing the Rationale for ADC and ICI Combinations in TNBC

Virginia Kaklamani, MD, DSc; Tiffany A. Traina, MD, FASCO

Multimedia

Expert Guidance on Frequently Asked Questions Regarding the Use of ADCs in TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Virginia Kaklamani, MD, DSc

Multimedia

Dissecting Clinical Trial and Real-World Data for ADCs in TNBC

Filipa Lynce, MD; Rita Nanda, MD

Video

Broadening the Frontline—Studies Informing the Use of Immunotherapy in Hepatocellular Carcinoma

Ghassan Abou-Alfa, MD, MBA; Laura Williams Goff, MD, MSCI, MMHC, FASCO; Arndt Vogel, MD, PhD

Audio

Practical Considerations and Future Directions for New Treatment Strategies in SCLC

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Misty D. Shields, MD, PhD

Multimedia

Expert Roundtable and Panel Discussions: Current and Future Landscape of TNBC

Aditya Bardia, MD, MPH, FASCO; Erika P. Hamilton, MD; Tiffany A. Traina, MD, FASCO

Audio

Navigating Treatment Gaps in SCLC: Relapse, Resistance, and Need for New Options

Rahul Gosain, MD, MBA; Rohit Gosain, MD; Giannis Mountzios ΜD, PhD

Video

Medical Crossfire® in Adjunctive Testing: Charting a New Course in Prostate Cancer Risk Assessment

Jason Hafron, MD; Aaron D. Berger, MD; Arpeet Shah, MD

Multimedia

BURST CME™ Resource Center: Integrating Novel PSMA-Directed Radioligand Approaches for Diagnosis and Management of Prostate Cancer

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Nerina McDonald, MSPAS, PA-C; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Radioligand Therapy 101: The Science Behind the Strategy

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

Multimedia

Imaging Matters: Decoding PSMA PET for Better Decision-Making

Jeremie Calais, MD, PhD; Tanya B. Dorff, MD; Scott T. Tagawa, MD, MS, FACP, FASCO

More News

The Role of Transplant in Newly Diagnosed Multiple Myeloma

ByPeter Voorhees, MD,Kwabena Osei-Boateng, MD,Amy Soni, MD,Reed Friend, MD

August 30th 2023

A panel of experts on multiple myeloma discuss the decision to refer patients with newly diagnosed multiple myeloma for transplant.

Induction Treatment Regimens for Patients With Transplant-Eligible NDMM

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

August 29th 2023

A panel of experts from City of Hope and satellite clinics review the available frontline therapy options for patients with transplant-eligible newly diagnosed multiple myeloma.

Clinical Scenario: A 61-Year-Old Woman with Transplant-Eligible Newly Diagnosed Multiple Myeloma (NDMM)

ByMichael Rosenzweig, MD, MS,Ashwin Kashyap, MD,Neel Talwar, MD,Natasha Garg, DO, MS

August 29th 2023

Michael Rosenzweig, MD, MS, presents the clinical scenario of a 61-year-old woman with transplant-eligible newly diagnosed multiple myeloma to the panel for discussion.

$Findings from the phase 1/2 MajesTEC-1 study support the European Commission’s approval of teclistamab at a reduced dose frequency for patients with relapsed/refractory multiple myeloma.$

Reduced Dose Teclistamab Earns European Approval in R/R Multiple Myeloma

ByRuss Conroy

August 28th 2023

Findings from the phase 1/2 MajesTEC-1 study support the European Commission’s approval of teclistamab at a reduced dose frequency for patients with relapsed/refractory multiple myeloma.

At an Around the Practice, experts from Emory University gathered to discuss treatment options for patients with multiple myeloma who are transplant-eligible or ineligible.

Determining Who Should Get Quadruplet Vs Triplet Therapy in Multiple Myeloma

ByAriana Pelosci

August 26th 2023

At an Around the Practice, experts from Emory University gathered to discuss treatment options for patients with multiple myeloma who are transplant-eligible or ineligible.

Identifying and Managing Infections in BCMA Therapy in Multiple Myeloma

ByONCOLOGY Staff

August 23rd 2023

Experts in the field of multiple myeloma highlight key takeaways for clinicans to be aware of for infections associated with bispecific antibody multiple myeloma treatments.

$The FDA allows for expanded bridging therapies in addition to other trial protocol amendments to enable investigators to continue their evaluation of CART-ddBCMA in relapsed/refractory multiple myeloma.$

FDA Lifts Hold on Phase 2 CART-ddBCMA Trial in R/R Multiple Myeloma

ByRuss Conroy

August 20th 2023

The FDA allows for expanded bridging therapies in addition to other trial protocol amendments to enable investigators to continue their evaluation of CART-ddBCMA in relapsed/refractory multiple myeloma.

Adverse Effect Management for Bispecific Antibodies in Multiple Myeloma

ByONCOLOGY Staff

August 20th 2023

Saad. Z. Usmani, MD, leads a panel of experts in discussing toxicities associated with treatment for multiple myeloma.

Cross Q&A: Isa + KD in Relapsed/Refractory MM and Biochemical vs Clinical Progression

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 18th 2023

In the final cross Q&A session from the multiple myeloma module, panelists discuss implications of IKEMA and consider the importance of biochemical versus clinical progression.

Biochemical vs Clinical Progression in Relapsed/Refractory Multiple Myeloma

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 18th 2023

Expert Wilson Gonsalves, MD, shares clinical data in multiple myeloma centered on the distinction between biochemical versus clinical progression.

$Elranatamab-bcmm is now approved for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.$

Elranatamab Receives Accelerated Approval in R/R Multiple Myeloma

ByAriana Pelosci

August 14th 2023

Elranatamab-bcmm is now approved for patients with relapsed/refractory multiple myeloma who have received at least 4 prior lines of therapy.

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Frontline Forum: Real-World Practice in Newly Diagnosed Multiple Myeloma

ByJoselle Cook, MBBS, Mayo Clinic,Matthew James Pianko, MD,Luciano Costa, MD, PhD,Timothy Schmidt, MD

August 14th 2023

Experts discuss key data updates in real-world newly diagnosed multiple myeloma practices, and how these findings may change the treatment paradigm.

Relapsed/Refractory Multiple Myeloma: The IKEMA Study

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 11th 2023

Covering the first of two abstracts, Wilson Gonsalves, MD, reviews data from the IKEMA study of isatuximab KD in patients with relapsed/refractory multiple myeloma.

Cross Q&A: Isatuximab + Pom-Dex in Relapsed/Refractory Multiple Myeloma

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 11th 2023

Panelists from both the Mayo Clinic and UT Southwestern comment on data from ALLIANCE A061202 and consider the role of isatuximab in patients with relapsed/refractory multiple myeloma.

$Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.$

FDA Gives Talquetamab Accelerated Approval for R/R Multiple Myeloma

ByAriana Pelosci

August 10th 2023

Patients with relapsed/refractory multiple myeloma may now receive talquetamab following the agent’s accelerated approval by the FDA.

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023

ByRafael Fonseca, MD,Krina K. Patel, MD, MSc

August 7th 2023

Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.

Relapsed/Refractory Multiple Myeloma: The ALLIANCE A061202 Study

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 4th 2023

Adeel Khan, MD, MPH, MS, expert in multiple myeloma management, reviews data from the ALLIANCE A061202 trial of isatuximab + pomalidomide + dexamethasone in relapsed/refractory disease.

Treatment Considerations for Bispecific Antibodies and Unmet Needs in MM

ByAl-Ola Abdallah, MD,Leyla O. Shune, MD,Nausheen Ahmed, MD,Jordan Snyder, PharmD

August 4th 2023

The expert panel overviews factors to consider with bispecific antibodies and offers closing insights on unmet needs in the multiple myeloma treatment space.

Cross Q&A: Ciltacabtagene Autoleucel in Relapsed/Refractory Multiple Myeloma

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

August 4th 2023

Experts from the Mayo Clinic and UT Southwestern share insight on the CARTITUDE-4 study and ciltacabtagene autoleucel in the second cross Q&A session.

Relapsed/Refractory Multiple Myeloma: Practice Pearls and Future Directions in Care

ByThomas G. Martin, MD,Ajay K. Nooka, MD,Jeremy Larsen, MD

August 4th 2023

Thomas Martin, MD; Ajay Nooka, MD; and Jeremy Larsen, MD, share closing thoughts on the evolving landscape of cytokine release syndrome management in relapsed/refractory multiple myeloma.

Relapsed/Refractory Multiple Myeloma: An Evolving Treatment Landscape

August 3rd 2023

Closing out their program on relapsed/refractory multiple myeloma, Ajai Chari, MD, and Carolina Schinke, MD, consider optimal treatment strategies in the current landscape and look toward future directions in care.

Recap: Available Treatment Options in Transplant-Eligible Multiple Myeloma

ByONCOLOGY Staff

July 30th 2023

Experts in the multiple myeloma space discuss recent developments and how to implement new practices in real-world settings.

Relapsed/Refractory Multiple Myeloma: The CARTITUDE-4 Study

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

July 28th 2023

Key opinion leader Prashant Kapoor, MD, FACP, shares data from the CARTITUDE-4 study of ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

BCMA Bispecific T-Cell Engagers in the Treatment of MM

ByAl-Ola Abdallah, MD,Leyla O. Shune, MD,Nausheen Ahmed, MD,Jordan Snyder, PharmD

July 28th 2023

Nausheen Ahmed, MD, gives an overview of BCMA bispecific T-cell engagers used in the treatment of multiple myeloma.

Cross Q&A: Idecabtagene Vicleucel in Relapsed/Refractory Multiple Myeloma

ByLarry Anderson, MD, PhD,Adeel Khan, MD, MPH, MS,Prashant Kapoor, MD,Wilson Gonsalves, MD,Abhishek Mangaonkar, MBBS,Kebede Begna, MD

July 28th 2023

Panelists follow up with questions and comments on the KarMMa-3 study in relapsed/refractory multiple myeloma and consider how idecabtagene vicleucel might fit into real-world practice.